Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eptinezumab

- PMLiVE

Lundbeck’s Steve Turley re-elected as EMG chair

And Actelion's Robin Bhattacherjee retains vice-chair position

- PMLiVE

Lundbeck launches alcohol drug Selincro in Europe

Norway, Finland, Poland and the Baltic countries chosen as first markets

Pharma deals during March 2013

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month

- PMLiVE

Battle lines drawn as Valeant ups Obagi bid

Hits back against Merz offer

- PMLiVE

Otsuka licenses Lundbeck’s Alzheimer’s drug in $825m deal

Lu AE58054 is in phase III development as add-on to donepezil

- PMLiVE

Otsuka and Lundbeck extend CNS collaboration

Follows US approval of depot antipsychotic Abilify Maintena

PRA acquires ClinStar to expand in Eastern Europe

CRO will manage clinical trials in Russia, Ukraine, Belarus and the Baltic States

Pharma deals during February 2013

Deal Watch: Major pharma collaborations, acquisitions and agreements in the past month

- PMLiVE

Depot Abilify approval in US buoys Lundbeck and Otsuka

FDA licences the once-monthly version of Lundbeck's blockbuster schizophrenia drug

- PMLiVE

Lundbeck’s alcohol dependency drug approved in Europe

Selincro is the first drug approved to reduce alcohol consumption

- PMLiVE

Mylan agrees $1.6bn deal to buy Agila injectables unit

Generics firm becomes “top three player” in injectables

- PMLiVE

Royalty Pharma mulls bid for Elan

Follows Biogen’s $3.25bn acquisition of Tysabri from Elan

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links